Drug Profile
KHK 6640
Alternative Names: KHK-6640Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Immunas Pharma
- Developer Kyowa Kirin
- Class Antidementias; Monoclonal antibodies; Peptides
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Alzheimer's-disease in Serbia (IV)
- 31 Mar 2023 Discontinued - Phase-I for Alzheimer's disease in Japan, Belgium, Finland, Netherlands, Sweden (IV)
- 06 Aug 2021 KHK 6640 is still in phase I trials for Alzheimer's disease in Serbia, Sweden, Netherlands, Japan, Finland, Belgium (Kyowa Kirin pipeline, August 2021)